Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2009

UCB Taps Proteros for Structure-Based Drug Discovery

  • UCB is employing Proteros biostructures to support structure-based discovery of small molecule drugs. Proteos will receive research fees and milestones.

    Initially, Proteros will leverage its expertise in gene-to-structure projects and its technologies to solve the 3-D structure of an undisclosed target together with its related proteins.

    After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of confirming the binding modes to the proteins. This will facilitate medicinal chemistry research and optimization of small molecules, the companies say.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »